32 results about "Apoptosis Inhibitor" patented technology

The invention provides a cell sheet cryopreservation solution. The cell sheet cryopreservation solution comprises a cryoprotectant, a buffer solution, a reducing agent, a calcium ion channel inhibitor and an apoptosis inhibitor. The invention also provides a method for cryopreserving the cell sheet by using the cell sheet cryopreservation liquid. According to the cell sheet cryopreservation liquid and the method for cryopreserving the cell sheet, the structural integrity and the cell activity of the cell sheet can be kept.

The invention discloses a stem cell-derived function-enhanced mesenchymal stromal cell as well as a preparation method and application thereof. The preparation method comprises the following steps: inserting an IL-10 gene coding sequence and a CD47 gene coding sequence into a human pluripotent stem cell; a neural crest cell differentiation culture medium containing a Wnt pathway agonist and an ALK5 inhibitor is used for carrying out induced differentiation culture on the CD47 positive human pluripotent stem cells to obtain the neural crest cells. The neural crest cells are subjected to induced differentiation culture by adopting a transition culture medium containing an epidermal growth factor, a fibroblast growth factor 2 and a cell apoptosis inhibitor and a mesenchymal stromal cell differentiation culture medium containing the epidermal growth factor, the fibroblast growth factor 2 and a platelet growth factor in sequence; according to the present invention, with the combination of the specific embodiments, the obtained mesenchymal stromal cell highly expresses CD47 and IL-10, the expression of the CD47 can help the transplanted cell escape from the attack of the immune system and prolong the cell survival time, and the expression of the IL-10 can be used for anti-inflammation.

The invention relates to the technical field of biology, and particularly discloses a supercooled cell preserving fluid as well as a preserving method and application thereof. The preserving fluid is mainly prepared from RPX basic cell preserving fluid, an energy substrate, a calcium ion channel blocker, a Na < + > / H < + > exchange channel inhibitor, a colloid impermeable cell protective agent, a cell apoptosis inhibitor, an antioxidant, an inflammation inhibitor, a colloid osmotic pressure regulator, a PH regulator and the like according to a certain proportion. According to the preservation method, the cells are preserved under the subcooling condition of-1 DEG C to-7 DEG C, the cell metabolism rate is reduced to the maximum extent, meanwhile, structural and functional damage caused by freezing to the cells is eliminated, and the effect that the survival rate of the recovered cells exceeds 80% after the cells are preserved for more than 18 months under the non-freezing condition is achieved; the application opens up a way for long-term non-freezing preservation of special functional cells of cells and genetic engineering and clinical cell treatment products, provides an effective method, and lays a foundation for starting a new stage of non-freezing long-term preservation of the cells.

The invention provides an agent for the treatment or prophylaxis of a neurodegenerative disease, containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment.

The present disclosure provides a cell patch cryopreservation solution, which includes: a cryoprotectant, a buffer, a reducing agent, a calcium channel inhibitor and an apoptosis inhibitor. The present disclosure also provides a method of cryopreserving a cell patch by using the aforementioned cell patch cryopreservation solution. The cell patch cryopreservation solution and the method of cryopreserving a cell patch provided by the present disclosure can maintain the structural integrity and the cell activity of the cell patch.

It relates to 1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho [2, 3-d]imidazolium pamoate or solvate thereof, pharmaceutical composition comprising the pamoate salt or solvate, and therapeutic uses thereof. In particular, the pamoate salt or solvate is useful for treating cancer which has a c-My rearrangement and / or MYCN amplification or overexpression.

The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to API5 according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.

The present invention relates to a urine sample stabilization protection solution and its application in biomarker detection, belonging to the technical field of application of urine in biomarker detection after storage and transportation at room temperature. The urine sample stabilization preservation solution is composed of physiological saline, preservatives, co-solvent stabilizers, inhibitor compositions and surfactants in a certain proportion; the inhibitor compositions are protease inhibitors, nuclease inhibitors and cell apoptosis inhibitors. The urine sample stabilization preservation solution is used for room temperature storage of urine samples, which can prevent the degradation of proteins, peptides and nucleic acids in urine under room temperature conditions, prevent enzyme inactivation, prevent cell lysis and inhibit the growth of microorganisms, maintain osmotic pressure and pH stability, and maintain the integrity and activity of cells and biomarkers; after adding the preservation solution, the urine sample is stored at room temperature for no less than 30 days to ensure the accuracy and reproducibility of marker detection.

The present disclosure relates to 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2, 3-d]imidazolium molybdate or a solvate thereof, crystalline forms thereof, pharmaceutical compositions comprising the molybdate salt or solvate, and therapeutic uses thereof. In particular, the molybdate salt or solvate is useful for treating cancer, such as a cancer having a c-Myc rearrangement and / or MYCN amplification or overexpression.

The present disclosure provides compositions and methods useful in treating heart conditions. The disclosed compositions and methods encompass gene therapies including a recombinant AAV vector for delivering two or more transgenes into the heart of a human subject. The two or more transgenes comprise an S100A1 protein and a cardiac Apoptosis Repressor with Caspase Recruitment Domain (cARC) apoptotic inhibitor. The disclosure also provides vectors comprising S100A1 and / or cARC cDNA sequences that are codon-optimized for expression in humans.

The invention provides a cell culture solution as well as a preparation method and application thereof. The cell culture fluid comprises a basic culture medium, an auxiliary synergistic component, a microenvironment regulation and control component, a stability regulation and control component and a balling induction component, the auxiliary synergistic component comprises an RHO related kinase inhibitor, an antioxidant, a serum substitute, a cell adhesion enhancer and an apoptosis inhibition factor, the microenvironment regulation component comprises a growth factor, the stability regulation component comprises a surfactant and a buffer agent, and the balling induction component comprises at least one polyglycerol ester. The technical defects that a traditional stent-free system is low in balling efficiency, long in period and insufficient in stability are overcome, and meanwhile high cost, batch difference and clinical safety risks caused by introduction of additional materials of a stent system are avoided; the technical problems of insufficient efficiency, poor uniformity and poor stability generally existing in three-dimensional cell balling culture are solved.

To provide novel agents for preventing and / or treating kidney stones.SOLUTION: Provided is an agent for inhibiting the growth of kidney stones, comprising a peptide containing an amino acid sequence that satisfies the following conditions, or a nucleic acid encoding the peptide: (1) an amino acid sequence of 20 or more consecutive amino acids in a region consisting of an SRCR1 domain and a hinge region of apoptosis inhibitor of macrophage (AIM); and (2) (the number of aspartic acid and glutamic acid in the amino acid sequence) - (the number of arginine and lysine in the amino acid sequence)≥5.SELECTED DRAWING: None

The present invention provides an agent for suppressing oxidative stress, the agent including at least one of the following (1)-(4): (1) apoptosis inhibitor of macrophage (AIM); (2) an AIM fragment including the SRCR2 domain of the AIM; (3) a modified object of the AIM or the AIM fragment, the modified object having an amino acid sequence that has an identity of 90% or more with respect to the AIM or the AIM fragment (no substitution is present in a free cysteine residue in the SRCR2 domain); and (4) a nucleic acid encoding the AIM, the AIM fragment, or the modified object thereof.

The present invention relates to polycyclic compounds and methods for targeted degradation of rapidly accelerated fibrosarcoma polypeptides. The present disclosure relates to bifunctional compounds, ULM-L-PTM, which are useful as modulators of rapidly accelerated fibrosarcoma. In particular, the disclosure relates to bifunctional compounds containing on one end a Von Hippel-Lindau, human cerebellar protein, apoptosis inhibitor protein, or a mouse double minute homolog 2 ligand that binds to the corresponding E3 ubiquitin ligase, and on the other end a moiety that binds to the target protein RAF, the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the target protein. The present disclosure exhibits a wide range of pharmacological activities associated with degradation / inhibition of a target protein.

To provide a method for stabilizing and isolating a plurality of biological targets contained in a cell-containing body fluid.SOLUTION: (A) providing a stabilized cell-containing body fluid sample by contacting a cell-containing body fluid with a stabilizing composition comprising one or more of the following stabilizing factors: (a) at least one primary, secondary or tertiary amide, (b) at least one poly (oxyethylene) polymer, and / or (c) at least one apoptosis inhibitor, (B) maintaining the stabilized cell-containing body fluid sample for a stabilization period, (C) determining the presence or absence of a cell subpopulation, extracellular nucleic acids, extracellular vesicles, and treating the stabilized cell-containing body fluid sample to enrich three or more biological targets selected from the group consisting of intracellular nucleic acids from the stabilized cell-containing body fluid. The method allows for multimodal analysis of different biological targets from a single stabilized cell-containing body fluid sample.SELECTED DRAWING: None

The invention discloses an antisense oligonucleotide of a coding gene of a targeted apoptosis inhibitor protein BIRC6, and the antisense oligonucleotide can down-regulate the expression ability of the BIRC6 gene in hematopoietic stem cells and promote the apoptosis initiation of senescence hematopoietic stem cells, so that the survival advantage of the senescence hematopoietic stem cells is inhibited, the senescence of the hematopoietic stem cells is reversed, and the hematopoietic stem cells can be inhibited. The invention also discloses the antisense oligonucleotide and application of the antisense oligonucleotide in preparation of apoptosis regulation and control drugs and tumor treatment drugs.

The present invention relates to polycyclic compounds and methods for targeted degradation of rapidly accelerated fibrosarcoma polypeptides. The present disclosure relates to bifunctional compounds, ULM-L-PTM, which are useful as modulators of rapidly accelerated fibrosarcoma. In particular, the disclosure relates to bifunctional compounds containing on one end a Von Hippel-Lindau, human cerebellar protein, apoptosis inhibitor protein, or a mouse double minute homolog 2 ligand that binds to the corresponding E3 ubiquitin ligase, and on the other end a moiety that binds to the target protein RAF, the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the target protein. The present disclosure exhibits a wide range of pharmacological activities associated with degradation / inhibition of a target protein.

The invention relates to the technical field of cell cryopreservation, and discloses a blastocyst vitrification refrigerating fluid set and application, the refrigerating fluid set comprises a basic buffer solution, a composite permeable protective agent, a non-permeable protective agent, a thermosensitive macromolecule regulating agent, a molecular state locking agent, a zwitterionic osmotic pressure buffer agent, a cell apoptosis inhibitor and an efficient antioxidant, the invention further provides a preparation method of the blastocyst vitrification refrigerating fluid set. The preparation method comprises the following steps: weighing HEPES in a clean container; gradually adding ethylene glycol and dimethyl sulfoxide into the basic buffer solution according to a ratio of 1: 1; slowly adding trehalose into the mixed liquid; slowly adding poloxamer into the transparent solution; then adding chondroitin sulfate; proline is gradually added; the preparation method comprises the following steps: adding a generic caspase inhibitor Z-VAD-FMK; and then adding the L-glutathione. According to the method disclosed by the invention, the blastocyst is subjected to cryoprotection by adopting the impermeable protective agent trehalose, so that the cell survival rate is remarkably improved.

The invention discloses a preparation method of a kidney-like organ with an increased in-vitro proximal tubule proportion, and belongs to the field of cytology. The method comprises the following steps: inducing kidney organs by using human embryonic stem cells WIBR3, culturing the WIBR3 cells until the WIBR3 cells can be passaged, and digesting the WIBR3 cells by using Accutase digestive juice; after the digestion is completed, stopping the digestion by using a DMEM-F12 culture medium, collecting a cell suspension, centrifuging, discarding supernate, collecting cell precipitates, and counting; resuspending the collected cell precipitate by using a stem cell culture medium, paving the cell precipitate in a pore plate, adding an apoptosis inhibitor, and uniformly mixing; and carrying out suspension culture on the obtained system by using a kidney organ culture medium for promoting the differentiation of the proximal tubules to obtain the kidney organs with the proportion of the proximal tubules increased. The preparation method is simple, the culture efficiency is high, and the prepared kidney organ with the increased proximal tubule proportion can effectively simulate the kidney organ with the increased proximal tubule proportion in vivo and can also be used for chemical substance kidney toxicity detection.

The present invention discloses a culture medium, method, model and application of a primary hepatocyte culture 3D liver model, and relates to the field of biotechnology. The culture medium includes: 100 μL of Williams E solution, 200 nmol~2 μmol of apoptosis inhibitor, 1.5~2.5 mmol of amino acid, 0.1~5.2 mg / ml of antibiotic, 3~8 ng / ml of sodium selenite, 3~8 μg / ml of transferrin, 8~12 nmol of steroid compound, 40~60 μmol of adenylate cyclase activator, 8~12 μmol of TGF-β inhibitor, and 8~20 μL of fetal bovine serum. The culture medium can maintain the long-term stability of cell function in vitro.

The present disclosure relates to 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2, 3-d] imidazolium molybdate or a solvate thereof, crystalline forms thereof, pharmaceutical compositions comprising the molybdate salt or solvate, and therapeutic uses thereof. In particular, the molybdate salt or solvate is useful for treating cancer, such as a cancer having a c-Myc rearrangement and / or MYCN amplification or overexpression.

The present invention provides an agent for the treatment or prophylaxis of a neurodegenerative disease, containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment.

The invention relates to the technical field of drugs, and relates to an engineered long-acting platelet delivery system internally loaded with a therapeutic drug as well as a preparation method and application of the engineered long-acting platelet delivery system. The system comprises platelets internally loaded with therapeutic drugs and nanoparticles containing platelet apoptosis inhibitors. The engineering long-acting platelet delivery system provided by the invention can realize in-vitro stable storage and in-vivo long-term circulation. Besides, according to the engineering long-acting platelet delivery system disclosed by the invention, accurate targeting of postoperative residual tumor cells and circulating tumor cells can be realized through efficient and natural wound tropism and tumor targeting of platelets, so that killer chemotherapeutic drugs are released, and postoperative tumor recurrence and metastasis are effectively avoided.

The invention discloses antisense oligonucleotide of a coding gene of targeted apoptosis inhibition protein BIRC6, and the antisense oligonucleotide and a nano-material carrier loaded with the antisense oligonucleotide can reduce expression ability of the BIRC6 gene in hematopoietic stem cells in a targeted manner, inhibit survival advantages of senescence hematopoietic stem cells and medullary system biased differentiation, reverse senescence of the hematopoietic stem cells, and inhibit apoptosis of the hematopoietic stem cells. The invention also discloses application of the antisense oligonucleotide and the nano-material carrier loaded with the antisense oligonucleotide in preparation of anti-aging drugs, drugs for promoting hematopoietic reconstitution after transplantation and immunomodulator drugs, and also discloses application of the antisense oligonucleotide and the nano-material carrier loaded with the antisense oligonucleotide in preparation of anti-aging drugs, drugs for promoting hematopoietic reconstitution after transplantation and immunomodulator drugs.

To provide a method for manufacturing a tumor-reactive T-cell.SOLUTION: A method includes: a step of culturing a T-cell by a process including incubating a cell cluster including a biological sample-derived T-cell which is obtained from a subject having a tumor together with a first T-cell stimulus substance for creating a stimulated T cell cluster, co-culturing the stimulated T-cell cluster in the presence of an antigen-presenting cell (APC), by which a cluster containing a T-cell which includes a tumor-reactive T-cell is created, creating a T-cell cluster in which the tumor-reactive T-cell is enriched from a co-cultured product, and incubating the T cell cluster, in which tumor-reactive T-cell is enriched, together with a second T-cell stimulus substance, where the step is performed in the presence of at least one T-cell adjuvant being an apoptosis inhibitory substance; and a step of collecting a created cell.SELECTED DRAWING: None

The present invention relates to a composition comprising a nucleic acid encoding a human-derived survivin polypeptide comprising at least three mutations compared to a natural human-derived survivin polypeptide, said composition being capable of eliciting a tumor-specific humoral or cellular immune response.

The present invention addresses the problem of providing a culture medium for long-term culture of hepatocytes while maintaining the bile canaliculi thereof. The present invention relates to a medium for culturing hepatocytes while maintaining the bile canaliculi that contains, as an active ingredient, one or more selected from the group consisting of AMPK activators, Epac activators, apoptosis inhibitors, and antioxidants, and to a method for maintaining the bile canaliculi that includes culturing hepatocytes using the medium.

This invention belongs to the fields of biotechnology and precision oncology, and discloses a serum-free amplification method for circulating tumor cells (CTCs) based on apoptosis selectivity, along with a dedicated culture medium. This addresses the problems of existing CTC technologies, which rely on physical capture leading to impaired cell viability and low culture success rates. The invention involves mild density gradient centrifugation and erythrocyte lysis of anticoagulated whole blood from patients to obtain a mixed population of leukocytes containing CTCs. This population is then seeded into a serum-free, selective apoptosis medium for three-dimensional culture. The medium contains apoptosis inhibitors and specific growth factors. Utilizing the difference between tumor cells' anti-apoptosis and normal blood cells' susceptibility to apoptosis, leukocyte apoptosis is induced within 4-7 days, while simultaneously supporting CTC survival, adhesion, and clonal proliferation, enabling the amplification of individual CTCs into cell clusters. This method preserves the original activity and heterogeneity of CTCs, is simple to operate, and has good reproducibility, providing a highly active cell source for CTC molecular identification, drug sensitivity testing, and metastasis mechanism research.

The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to API5 according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.

This invention relates to the field of pharmaceutical technology, specifically to an engineered long-acting platelet delivery system for loading therapeutic drugs, its preparation method, and its applications. The system comprises platelets loaded with therapeutic drugs and nanoparticles containing platelet apoptosis inhibitors. The engineered long-acting platelet delivery system of this invention enables stable in vitro storage and long-term in vivo circulation. Furthermore, by leveraging the efficient and natural wound tropism and tumor targeting properties of platelets, this system can precisely target residual and circulating tumor cells after surgery, thereby releasing cytotoxic chemotherapeutic drugs and effectively preventing postoperative tumor recurrence and metastasis.